Lifestyle Modifications

Slides:



Advertisements
Similar presentations
Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
Advertisements

Diabetes in Pregnancy Screening.
INSULIN STRATEGIES IN TYPE 2 DIABETES. The epidemic of type 2 diabetes and the recognition that achieving specific glycemic goals can substantially reduce.
A1C 6.5 – 7.5% ** Monotherapy MET + GLP-1 or DPP4 1 TZD 2 Glinide or SU 5 TZD + GLP-1 or DPP4 1 MET + Colesevelam AGI Mos. *** Dual Therapy MET.
Diabetes Medication: Initiation and Intensification Gregory A. Nichols, PhD Annual Collaborative Diabetes Education Conference for Health Professionals.
Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.
Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Practical Implementation as a Discussion with the Patient, Part 2 Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 1 of 5.
Diabetes Update Part 2 of 3 Division of Endocrinology
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 1.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Therapy of Type 2 Diabetes Mellitus: UPDATE
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.
Adding Prandial Insulin to Basal Insulin: Key Challenges
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Current Classification of DM Update on Diabetes Classification Celeste C. Thomas, MD, MSa,*, Louis H. Philipson, MD, PhD,Med Clin N Am 99 (2015) 1–16.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
A Process Of Precision Medicine- Matching Right Drug to Right Patient.
What's New in Basal Insulin for Diabetes
CV Risk of SU and Insulin
Diabetes Learning Event 7th October 2016
Once Upon a Time, Insulin Resistance was Adaptive… but Not Today
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Management of Diabetes in the Older Person
A Process Of Precision Medicine- Matching Right Drug to Right Patient
NATURAL HISTORY OF BETA CELL FAILURE IN T2DM
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Most Mechanisms of B-Cell Damage (Hyperglycemia) Overlap with Causes of Vascular Disease : Provides Logic for Treatment Regimes and CV Benefits.
Initiation of Basal Insulin- not bolus
In T2DM, β-Cell Mass in Islets is Significantly Reduced
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Targets for Therapies/ New Guidelines
Pushback What about ‘pure’ Insulin Resistance Syndromes?
CV Risk of SU and Insulin
Management of Diabetes in the Older Person
What Comes Second?.
Choice of Therapy MYTH: “Most Patients with ‘T2DM’ will eventually
Updates Abound.
↑- likely due to hypoglycemia and weight gain
GLP-1 Receptor Agonists: How Early Is Appropriate?
Current Therapy for Type II Diabetes
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Disease Progression in Type 2 Diabetes
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Strategies for the Practical Management of Type 2 Diabetes
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
ADA/EASD general recommendations for type 2 diabetes management (1).
Carbohydrate absorption inhibitors α-glucosidose inhibitors
Once Upon a Time, Insulin Resistance was Adaptive… but Not Today
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Presentation transcript:

Lifestyle Modifications AACE/ACE: Recommendations Based on A1C at Diagnosis/ or When you see in Office EMPHASIS on Using Combination Therapy to ADDRESS multiple etiologies of hyperglycemia in Octet Lifestyle Modifications A1C 6.5%-7.5% A1C 7.6%-9.0% A1C > 9.0% If under treatment If drug naive Symptoms No symptoms Monotherapy Dual therapy Triple therapy Dual therapy Insulin plus other agent(s)* Insulin plus other agent(s)* Triple therapy Triple therapy Use Sulfonylureas/Glinides LAST, IF AT ALL Therapeutic Choice, based on Safety/ Efficacy, Should Match The Drug Characteristics With Patient Characteristics Rodbard HW, et al. Endocr Pract. 2009;15:540-559. 1

Issues 1. Tells you CONSIDER stopping SU- MUST 2. Doesn’t tell you what to do with other non-insulin therapies-CONTINUE 3. Doesn’t tell you use other non insulin agents before use prandial insulin since >80 % (conservative) of type 2 pts won’t require bolus insulin if on GLP-1 RA with SGLT-2 inhibitor +/- other

There is No perfect Exogenous Insulin: All result in HyperInsulinemia and Potential Hypoglycemia CONCLUSION: DELAY INSULIN THERAPY; AVOID BOLUS RX if possible NORMAL: Insulin into portal system and B-cell= Perfect glucose sensor- Insulin secretion modulator Exogenous Insulin

Philosophy for Reduced Insulin Need in T2DM 1. No Perfect Insulin Exogenous insulin not put in portal system; no fine-tuning a la Beta Cell 2. Leads to Hyperinsulinism- leads to Insulin Resistance (suppresses dopamine in ‘biologic clock’ of hypothalamus)– leads to Increased Weight, Hypoglycemia Risk 3. So Goal of all Insulin Therapy- Least Hypoglycemia, Least Weight Gain 4. Old Logic- use Early Insulin to reduce Glucotoxicity, Lipotoxicity but GLP-1 RAs and SGLT-2 Inh. do that first day!!, with no weight gain, no hypoglycemia 5. Therefore no need for Early Insulin- use 3-4 Non-Insulin therapy before go to Basal Insulin; keep Non-Insulin Therapies and 95% of T2DM won’t need Bolus Insulin (by avoiding bolus insulin reduce hypoglycemic risk 85%)

Uses Across Continuum of Care 1. Pre-Diabetes 2. Rest of Continuum of Care 3. AACE Guidelines, Triple RX before Insulin Pick Right Drug for Right Patient 4. Delay Need for Insulin No need for Early Insulin 5. If need Insulin, Continue Non-Insulin RX Avoids need for Meal-Time Insulin Decrease Risk Hypoglycemia 85% 6. Get Patients off insulin Had been given Early Insulin Colsevalam, ranolazine, AGI